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The largest described outbreak of chikungunya virus
has been occurring on the islands of the southwest Indian
Ocean since March 2005. We describe the manifestations
of chikungunya virus infection in travelers returning from
these islands, with focus on skin manifestations.
C
hikungunya virus is an arthropodborne virus (genus
Alphavirus, family Togaviridae) (1). It was first isolat-
ed in Tanzania in 1953 (2). Since then, chikungunya out-
breaks have been reported in Africa and Asia. Transmission
to humans occurs through bites of Aedes (mainly Aedes
aegypti and A. albopictus) mosquitoes (3–7).
An outbreak of chikungunya occurred in the Comoro
Islands in early 2005; since then, the virus has circulated to
other islands in the Indian Ocean. The first case of
chikungunya infection was identified in the Indian Ocean
island of Reunion in March 2005. After a period of lower
transmission during winter, case numbers increased dra-
matically with the arrival of the Southern Hemisphere
summer in December (8). The Reunion epidemic is the
largest ever described; ≈150,000 cases were reported from
March 2005 through February 2006. We describe skin
manifestations of this chikungunya infection in travelers
returning from the area.
The Study
All adult travelers who came to our tropical diseases
unit from March 2005 through February 2006 were
prospectively included in this study if they had symptoms
of chikungunya virus infection after traveling to any island
in the southwest Indian Ocean (Comoro, Mauritius,
Mayotte, Reunion, Seychelles). Children <5 years of age
were not included because no pediatricians practiced in our
hospital. Chikungunya virus was suspected if fever, joint
pain, or skin eruption was present. Diagnosis of
chikungunya infection was confirmed by an immunocap-
ture ELISA derived from a yellow fever test by using a
goat anti-human immunoglobulin (Ig) M antibody (Sigma,
Saint Louis, MO, USA), an inactivated cell-culture–grown
chikungunya virus and a mouse anti-chikungunya hyper-
immune ascitic fluid (Institut Pasteur, Lyon, France), and a
horseradish peroxidase–labeled antimouse IgG conjugate
(Sigma) (9). Other blood tests were performed according
to the discretion of the physician in charge of the patient. 
During the study period, chikungunya infection was
confirmed serologically in 22 patients (14 female, 8 male);
median age was 47 years (25–72 years). Seventeen
patients had returned from Reunion (77%), 3 from Comoro
(14%), and 2 from Mauritius (9%). Twelve (55%) patients
were tourists, 8 (36%) were islanders settled in France but
returning from visiting their relatives, and 2 (21%) were
French residents in these islands. The median duration of
stay (residents excluded) was 21 days (2–90 days).
Symptoms appeared in 19 (86%) patients while they were
abroad and within 3 days of return in 3 patients (14%). The
median lag time between onset of symptoms and consulta-
tion was 13.5 days (range 2 days–9 months).
Fever and joint pain were noted in all patients. The
median duration of fever was 4 days (range 2–7 days), and
joint pain was mainly distal and symmetric, involving
wrist (18 patients, 81%), ankles (17 cases, 77%), phalanx
(16 patients, 73%), knees (14 patients, 64%), and elbows
and shoulders (4 patients each, 18%). The other extrader-
matologic signs were asthenia in 17 patients (77%),
headache in 13 (59%), muscle pain in 12 (55%), swelling
in 10 (45%), peripheral lymphadenopathy in 9 (41%),
bleeding from the nose or gums in 4 (18%), nausea or
vomiting in 3 (14%), and eyesight trouble in 1 (4%). In the
6 patients seen during the first week of symptoms (acutely
ill patients), lymphopenia was present in 67%, thrombocy-
topenia in 50%, and increase of alanine aminotransferase/
aspartate aminotransferase in 67%.
Skin manifestations occurred in 17 patients (77%).
Because skin eruption occurs during the first week of the
disease, however, only 6 (27%) patients with these signs
were seen at the time of consultation. All 6 had a general-
ized exanthema consisting of noncoalescent macular or
papular lesions (Figure). The elementary cutaneous ele-
ment was an erythematous macule in 5 patients and macu-
lopapules in 1. The number of macules was >50, and the
anatomic location of the rash was abdomen, thorax, back,
and limbs. No lesions were seen on the face; palms and
soles were involved in 3 patients. Islands of normal skin
were seen in 5 patients. An aphthoid lesion was seen in 1
patient. Pruritus of the skin or a burning sensation was
reported in 3 patients. Bleeding from the nose or gum, pur-
pura, petechiae, ecchymosis, and bullous lesions were not
observed. Erythema followed the onset of fever by 1 to 2
days, lasted 3–7 days, and disappeared without scaling in
all cases, regardless of the patient’s skin color.
The main complaint after the first week was persistent
arthralgia. The treatment was exclusively symptomatic:
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tions. 
The dramatic ongoing epidemic of chikungunya infec-
tion in the southwestern part of the Indian Ocean, particu-
larly Reunion Island, provided the opportunity to describe
the skin manifestations of this infection among travelers.
The main characteristic of the skin eruption was a general-
ized macular erythematous exanthema, often with islands
of normal skin and a sensation of pruritus. The infection
was also characterized by a short incubation period (1–12
days). Most patients had fever, arthralgia, exanthema,
asthenia, myalgia, and headache. 
Conclusions 
Among travelers returning from the tropics, febrile
exanthema associated with arthralgia is not specific to
chikungunya and may be observed with several other viral
and bacterial infections and adverse cutaneous reactions
(10). Chikungunya and dengue infections are probably the
most difficult to differentiate. The viruses are transmitted
by the same mosquito species; disease-endemic areas are
nearly the same in Asia, Africa, and the Indian Ocean; and
clinical symptoms are similar. In addition, simultaneous
coinfection with chikungunya and dengue viruses has been
reported (5,11). In the only published study comparing
chikungunya and dengue clinical manifestations in
Thailand, the onset of symptoms was more abrupt; the
febrile course was shorter; and maculopapular rashes, con-
junctival injection, and arthralgia were significantly more
frequent than in dengue (12). Shock and gastrointestinal
hemorrhages occurred only in dengue patients, but the
tourniquet test did not help to differentiate chikungunya
from dengue (12). The skin manifestations reported in our
study are similar to those described for classic dengue
fever infection, which is characterized by a pruritic, macu-
lar or a maculopapular rash in which small islands of nor-
mal skin are spared (12). 
The Alphavirus genus consists of 30 species of arthro-
podborne viruses (1,13). Of these, 6 mosquitoborne virus-
es are associated with fever, arthralgia, and rash: the Ross
River and Barmah Forest viruses in the South Pacific,
o’nyong-nyong and Sindbis viruses in tropical Africa,
chikungunya virus in Africa and Asia, and Mayaro virus in
South America. Symptoms are usually of short duration,
≈1 week, and complete recovery is the rule, except in some
cases of chikungunya infection, in which arthralgia may
last for months (14,15). Indeed, 7 patients in our study had
at least a 1-month duration of arthralgia; 1 patient consult-
ed us 9 months after the onset of disease. The clinical man-
ifestations reported in this study illustrate the difficulty in
differentiating chikungunya infection from classical
dengue fever but may help to differentiate this infection
from other causes of febrile exanthema in travelers.
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